Publications by authors named "Ning-lin Ge"
Article Synopsis
- A study explored the prognostic value of the albumin-to-alkaline phosphatase ratio (AAPR) in predicting outcomes for early-stage hepatocellular carcinoma (HCC) patients receiving radiofrequency ablation (RFA) as their first treatment.
- The analysis of 445 patients revealed that those with a low AAPR had significantly worse recurrence-free and overall survival rates compared to those with a high AAPR, establishing AAPR as an independent prognostic factor.
- An AAPR-based nomogram demonstrated strong predictive performance, with a concordance index of 0.72, suggesting it could be beneficial for personalized prognosis and clinical decisions in HCC management.
Background And Aim: Radiofrequency ablation (RFA) is recommended as one of the standard treatments for early hepatocellular carcinoma (HCC). Because of high-risk tumor locations unfit for RFA, transarterial chemoembolization (TACE) is served as an alternative option in these settings. To define the role of TACE on early HCC, we retrospectively compared the efficacies of TACE with RFA in patients with unresectable Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC.
View Article and Find Full Text PDFRadiofrequency ablation (RFA) has been used as a curative therapy for small hepatocellular carcinoma (HCC). However, relatively little is known about the long-term outcome of RFA for small HCC in a background of hepatitis B infection, which is common among the Chinese population. Between May 2001 and May 2012, 837 patients with HCC nodules ≤3 cm treated with RFA were enrolled in this study.
View Article and Find Full Text PDFBackground: This study was designed to evaluate the effectiveness of radiofrequency ablation in patients with intermediate (BCLC B) stage hepatocellular carcinoma who underwent transcatheter arterial chemoembolization.
Methods: Included in this study were 211 patients with intermediate stage HCC who underwent initial transcatheter arterial chemoembolization and were potentially amendable for radiofrequency ablation (single tumor with diameter 5-8 cm, median 6.0 cm; 2-5 multiple nodules with diameter less than 5 cm) between January 2005 and December 2011.
Background: Recent studies suggest that a combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have theoretical advantages over TACE alone for treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the effectiveness and safety of radiofrequency ablation following first-line TACE treatment in the management of HCC beyond the Milan Criteria.
Methods: Forty-five patients who consecutively underwent RFA following first-line TACE treatment for HCC beyond the Milan criteria were enrolled in this study.